Novo Nordisk A/S (NYSE:NVO) has been assigned a consensus rating of “Hold” from the thirteen brokerages that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $137.76.
A number of research analysts recently issued reports on the stock. Bank of America lifted their price target on shares of Novo Nordisk A/S from $355.00 to $400.00 and gave the company a “neutral” rating in a research report on Friday, September 13th. Pareto Securities cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. Jefferies Financial Group downgraded shares of Novo Nordisk A/S from a “hold” rating to an “underperform” rating in a research note on Friday, August 30th. Barclays raised Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, November 27th. Finally, UBS Group downgraded Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Monday, November 18th.
Shares of NYSE NVO traded up $0.65 during trading hours on Friday, hitting $57.17. The company’s stock had a trading volume of 78,978 shares, compared to its average volume of 1,519,480. Novo Nordisk A/S has a 12 month low of $43.60 and a 12 month high of $58.01. The stock has a market cap of $133.84 billion, a price-to-earnings ratio of 22.73, a P/E/G ratio of 2.26 and a beta of 0.61. The company has a debt-to-equity ratio of 0.06, a quick ratio of 0.73 and a current ratio of 1.00. The business has a 50-day simple moving average of $55.36 and a 200-day simple moving average of $51.57.
Large investors have recently added to or reduced their stakes in the stock. Cornerstone Advisors Inc. lifted its holdings in Novo Nordisk A/S by 5.0% in the second quarter. Cornerstone Advisors Inc. now owns 5,974 shares of the company’s stock valued at $305,000 after acquiring an additional 285 shares during the last quarter. AE Wealth Management LLC purchased a new position in Novo Nordisk A/S during the 2nd quarter valued at about $283,000. Cim LLC boosted its holdings in Novo Nordisk A/S by 2.0% during the 2nd quarter. Cim LLC now owns 196,089 shares of the company’s stock valued at $10,008,000 after acquiring an additional 3,861 shares during the period. Commerzbank Aktiengesellschaft FI boosted its holdings in Novo Nordisk A/S by 13.9% during the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 85,350 shares of the company’s stock valued at $4,356,000 after acquiring an additional 10,404 shares during the period. Finally, Arden Trust Co acquired a new position in Novo Nordisk A/S in the 2nd quarter valued at about $642,000. Hedge funds and other institutional investors own 7.32% of the company’s stock.
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Read More: What is Cost of Capital?
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.